How do we differentiate our telehealth brand when every competitor claims the same convenience and affordability?

In March 2026, Hims & Hers said it would stop advertising compounded GLP-1 offerings and move its U.S. weight-loss business toward FDA-approved options. That shift answers the positioning question: convenience, access, and price are unstable category claims, so a durable telehealth position must join a narrow patient situation to an operating behavior and proof that stays true when policy, supply, or pricing changes.

The $50 price reset made “affordable” even less ownable

Hims & Hers changed more than its message. Its March 2026 strategy announcement changed what the platform would advertise and which products it expected most patients to access. That is the positioning problem in miniature: a scaled company can change access and assortment through one agreement, making a competitor's matching access claim less distinct.

Then the floor moved again. The Centers for Medicare & Medicaid Services' GLP-1 Bridge began July 1, 2026, with a $50 copay for eligible Medicare Part D beneficiaries. The demonstration is scheduled to run through December 31, 2027.

This is not a reason to build a medication-specific brand. It is evidence that “affordable access” can be repriced by a manufacturer agreement or a federal program. A company that hangs its identity on being cheaper can lose its distinction without changing anything inside its own business.

Convenience has the same problem. Online intake, home delivery, discreet service, and access to licensed clinicians matter. They also describe the category. A competitor can add the same four bullets to a homepage this afternoon.

A useful position must answer a harder question: what does this company do differently when the patient journey becomes complicated?

Big competitors prove that the moat is a system

Hims & Hers reported $2.3476 billion in 2025 revenue, up 59% from 2024. Subscribers grew 13% to about 2.511 million. Personalized offerings represented more than 70% of U.S. revenue, and monthly revenue per average subscriber rose 28% to $83. Those figures come from the company's 2025 Form 10-K filed with the SEC.

Those numbers do not mean a smaller telehealth company should sound like Hims. They show why copying its surface language is a losing game. A scaled platform can combine national awareness, broad product access, onboarding tests, fulfillment, recurring billing, and large marketing budgets. “We make care easy” does not explain why a patient should choose the smaller company over that machine.

The smaller company needs a choosing reason that scale does not automatically supply. Examples include:

a defined continuity model for patients who are tired of repeating their story;
a narrow population whose barriers, schedule, or care context shape the entire service;
an unusually clear escalation path when virtual care is not appropriate;
a follow-up behavior with a named owner and stated response window;
a language-access or caregiver workflow built into the patient experience;
a care-team structure that makes a particular kind of coordination visible.

Each example contains a tradeoff. A service designed for one patient context will not be for everyone. A real escalation standard may send some people to in-person care. A continuity promise requires staffing and record access. The tradeoff is what keeps the promise from becoming another adjective.

Build a position from four linked parts

Use this chain:

Patient situation → unresolved friction → operating behavior → visible proof

1. Patient situation

“Adults seeking convenient virtual care” is too broad. Name the moment that makes the patient look for an alternative. It could be repeated handoffs, a confusing transition from intake to visit, trouble coordinating with existing care, or uncertainty about what happens after an async encounter.

Keep marketing fit separate from clinical eligibility. Positioning can describe whom the service was designed to help. Only an appropriate clinical evaluation can determine whether a specific person should receive care through that model.

2. Unresolved friction

Do not settle for “they want convenience.” Find the sharp edge inside it. Does the patient need a same-week administrative answer? Do they worry that nobody owns follow-up? Are they comparing a virtual visit with waiting three weeks locally? Do they need to understand the full cash cost before starting intake?

The friction should come from de-identified patient research, support conversations, intake exits, or sales calls. Compliments are weak inputs. “Easy” says little. Knowing who would answer if the plan changed points to a behavior worth examining.

3. Operating behavior

Write what the company must repeatedly do to resolve that friction. “Continuity” might require a shared record, a defined handoff, an accountable follow-up owner, and a referral path. “Transparent cost” might require a complete pre-intake fee explanation, rules for laboratory or pharmacy charges, and a process for handling an estimate that changes.

If the behavior cannot be observed, assigned, and audited, it is not a position yet. It is an aspiration.

4. Visible proof

Show the evidence before asking the patient to trust the adjective. Proof can be a clinician roster, a step-by-step escalation policy, named response times, pricing boundaries, a sample follow-up timeline, accreditation, or a clear explanation of what the service will not do.

Bad proof can damage trust. In 2023, the Federal Trade Commission alleged that GoodRx displayed a seal on its telehealth homepage that falsely suggested HIPAA compliance. The FTC action included a $1.5 million civil penalty. A trust badge is not evidence when the underlying practice cannot support it.

This is strategic guidance, not legal advice. Public claims should be reviewed against the actual service, applicable laws, platform rules, and the evidence the company can maintain.

What should we do before rewriting the homepage?

List the patient's real alternatives. Include waiting for a local appointment, returning to a fragmented service, asking a primary-care office, doing nothing, and choosing a large national platform. The position must beat a lived alternative, not an internal competitor slide.
Interview around decisions. Ask what triggered the search, what nearly stopped the person, what evidence reduced concern, and what happened after the first encounter. Remove protected health information before material reaches the marketing team.
Choose one valuable operating difference. Do not combine continuity, specialty depth, low price, speed, compassion, and personalization into one sentence. Pick the difference that matters most to a defined patient situation and that operations can sustain.
Write a falsifiable promise. Use: “For people in this situation, this service provides this difference because the model works this way.” If the sentence remains true after swapping in three competitor names, narrow it.
Create a promise-to-proof ledger. Give every proposed claim five fields: exact wording, supporting workflow, visible evidence, accountable owner, and review date. Unsupported language is removed. It is not rescued with “designed to” or “committed to.”
Make the boundary visible. State whom the model fits, what it prioritizes, and when another care setting may be more appropriate. A boundary can increase trust because it shows that access does not overrule clinical judgment.
Test comprehension, not preference. Ask best-fit prospects what they believe the promise means, what they expect to happen next, and which proof they need. Preference alone is not enough. A line that creates the wrong care expectation fails even when people remember it.
Audit delivery after launch. Review support tickets, intake exits, complaints, referrals, and follow-up misses against the promise. Positioning becomes defensible when the operating system keeps producing the promised experience.

What makes a continuity promise clinically credible

From Pranay Parikh, MD:

Continuity does not mean the same face. It means the patient never has to start over.

The best version is the same physician seeing them again, and it is worth engineering for. But it does not scale, and a telehealth company promising it at volume is either lying or about to be. So the real test is what happens when the second visit is with someone new. Does that clinician already know what was tried, what the patient said last time, and why the plan is what it is? Or does the patient tell the story again?

This is where AI actually earns its place in this category. Not writing the ad. Summarizing the patient so the context arrives before the clinician does, whether that clinician is new or the original one who has seen forty patients since.

The promise is ongoing care. The proof is that the second doctor opens the chart already caught up. If the patient repeats their history, you do not have continuity. You have a subscription.

A fast test for a real differentiator

Score a proposed position from zero to two on each question:

Specific patient: Does it name a recognizable situation rather than “everyone who wants better care”?
Meaningful friction: Does it resolve a problem patients can describe in their own words?
Operational cost: Would a competitor have to change staffing, workflow, policy, or product to copy it?
Visible proof: Can a patient inspect evidence before or during the experience?
Clinical boundary: Does it preserve clinician judgment and say where the promise stops?

This score is a heuristic, not a benchmark. Eight or more does not prove that the market will choose the position; it means the idea is concrete enough to test. Under five usually means the team is still arranging category credentials.

Get the positioning and differentiation worksheet by email to turn the audience, promise, tradeoff, and proof into one practical plan.

If the promise is still generic, sharpen the how to differentiate when everyone claims convenience before debating taglines. Use the how to differentiate a telehealth brand to choose whom the promise is for, then work the differentiation worksheet before a rebrand with real decision language. The broader differentiation worksheet connects those choices into one system.

FAQ

Is convenience ever a meaningful telehealth differentiator?

Convenience can support a position when the brand defines exactly what becomes easier and proves the operating behavior behind it. On its own, convenience is a category credential that most virtual-care competitors can claim.

Can a telehealth brand differentiate if competitors use the same technology stack?

Yes. A defensible difference can live in the patient situation served, the care-team handoff, the follow-up owner, the escalation path, and the boundaries the company states. A competitor would need to change operations, not only copy, to reproduce those differences.

How do we know whether a positioning claim is credible?

Trace the claim to a repeatable workflow, an accountable owner, visible evidence, and a review date. Then test what prospects think the claim means. If their interpretation exceeds what the service can deliver, rewrite it.